Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 19

Results For "PAS"

827 News Found

Royal Sense launches stergic dengue IgG/IgM rapid test
Healthcare | August 25, 2024

Royal Sense launches stergic dengue IgG/IgM rapid test

The Dengue IgG/IgM Rapid Test is a diagnostic tool used to detect antibodies against the dengue virus in blood samples


BioAge appoints former GSK CEO Jean-Pierre Garnier as Chair of its Board of Directors
People | August 23, 2024

BioAge appoints former GSK CEO Jean-Pierre Garnier as Chair of its Board of Directors

New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development


Sun Pharma introduces STARIZO in India for skin infections
News | August 23, 2024

Sun Pharma introduces STARIZO in India for skin infections

Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India


Health Ministry assures doctors of all possible efforts to ensure safety
Policy | August 19, 2024

Health Ministry assures doctors of all possible efforts to ensure safety

A committee to be formed to suggest measures for ensuring the safety of healthcare professionals


CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance
News | August 19, 2024

CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance

The emergence of new infections in India is a growing concern


HCAH Kolkata Center achieves NABH Certification
News | August 15, 2024

HCAH Kolkata Center achieves NABH Certification

Becomes the first rehab & recovery center in east India to earn NABH accreditation


Wockhardt Q1 FY25 revenue up 14%
News | August 12, 2024

Wockhardt Q1 FY25 revenue up 14%

EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year


Ami Organics reports Q1FY25 PAT lower 34% at Rs. 14.7 Cr
News | August 12, 2024

Ami Organics reports Q1FY25 PAT lower 34% at Rs. 14.7 Cr

Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore


Caplin Point listed on Forbes Asia’s “200 Best under a Billion” for 2024
News | August 11, 2024

Caplin Point listed on Forbes Asia’s “200 Best under a Billion” for 2024

The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity